Skip to main content

Cannabis and Chronic Pain: What the Evidence Shows — So Far

 

Cannabis As Schedule III 

Cannabis and Chronic Pain: What the Evidence Shows

Note on the evidence: For decades, cannabis research in the United States was constrained by its classification as a Schedule I substance, limiting access, funding, product consistency, and long-term clinical trials. With marijuana now moved to Schedule III, many of the most rigorous studies have only just become feasible. The findings summarized below reflect the best evidence available to date — not the full scope of what future research may reveal.

TL;DR

  • Cannabis and cannabinoids show modest pain relief, strongest for neuropathic chronic pain.
  • Major reviews (including the 2017 National Academies report) find cannabis is more effective than placebo for chronic pain, but effects are generally small.
  • Benefits vary by product, dose, and delivery method, with inhaled and THC-containing products showing stronger effects.
  • Adverse effects are usually mild and short-term (e.g., dizziness, dry mouth, nausea).
  • Evidence quality is moderate; larger and longer-term studies are still needed.

Several key studies and systematic reviews have examined the use of cannabis or cannabinoids for chronic pain, particularly neuropathic pain. Overall, the evidence suggests modest benefits, with outcomes varying by formulation, route of administration, and pain type.

Landmark Review

The 2017 National Academies of Sciences, Engineering, and Medicine (NASEM) report concluded that there is substantial evidence that cannabis or cannabinoids are effective for treating chronic pain in adults. Based on a comprehensive review of existing trials, the report found that patients treated with cannabinoids were more likely to experience a clinically significant reduction in pain symptoms compared to placebo. This report is frequently cited as a benchmark in cannabis research.

Major Systematic Reviews and Meta-Analyses

  • 2021 BMJ Systematic Review and Meta-Analysis: Analyzed 32 randomized controlled trials (RCTs) involving over 5,000 patients with chronic non-cancer and cancer-related pain. The review found moderate- to high-certainty evidence that non-inhaled medical cannabis or cannabinoids provided small to very small improvements in pain relief (e.g., higher likelihood of achieving ≥30% pain reduction), physical functioning, and sleep quality compared to placebo. Transient adverse effects such as dizziness and nausea were more common.
  • 2017 Meta-Analysis (Aviram et al.): Reviewed 43 RCTs and found cannabis-based medicines were associated with pain reduction, particularly for neuropathic pain and when administered via inhalation. However, overall effects were limited, and gastrointestinal side effects were more frequent with oral formulations.
  • AHRQ Living Systematic Review (updated 2025): Synthesizes placebo-controlled RCTs and observational studies. Findings indicate small benefits for pain severity with high-THC products, though overall certainty remains low due to short study durations, product variability, and methodological limitations.
  • 2018 Meta-Analysis (Stockings et al.): Reviewed 104 studies and reported a small but statistically significant effect for achieving ≥30% pain reduction (number needed to treat: 24). Evidence was strongest for neuropathic pain, but adverse events were more common (number needed to harm: 6).

Specific RCTs and Notable Findings

Evidence is strongest for neuropathic pain, including pain related to multiple sclerosis, HIV, and diabetes:

  • Trials of nabiximols (THC:CBD oromucosal spray, such as Sativex) in multiple sclerosis–related neuropathic pain demonstrated significant reductions in pain intensity and improvements in sleep quality.
  • Inhaled cannabis trials (e.g., Wilsey et al., 2008 and 2013) showed dose-dependent relief of neuropathic pain, with many patients achieving greater than 30% reductions in pain scores.
  • A phase 3 randomized controlled trial (2025) of a full-spectrum cannabis extract (VER-01) for chronic low back pain reported reductions in pain severity, improved physical function, and better sleep outcomes, without evidence of dependence.

For other chronic pain conditions such as fibromyalgia and cancer-related pain, results are mixed or limited, with several trials showing no significant benefit compared to placebo.

Overall Assessment

Across meta-analyses, cannabinoids appear to offer modest relief primarily for neuropathic chronic pain, typically corresponding to an average reduction of approximately 3–10 mm on a 100 mm visual analog pain scale. Benefits are often short-term, and the overall quality of evidence is moderate due to small sample sizes, short trial durations, and variability in cannabis products.

Adverse effects are usually mild and transient, including dizziness, dry mouth, nausea, and cognitive changes. More large-scale, long-term randomized controlled trials are needed to clarify optimal dosing, formulations, and effectiveness for specific pain conditions.

For clinical decision-making, consultation of recent professional guidelines (such as those from BMJ or relevant medical societies) is recommended.

Labels:

Comments

Post a Comment

People's Choice

A Thank You Letter To President Trump for Opening the Door to Cannabis Research

  Trump's Cannabis From Schedule I to Schedule III Move Dear President Trump, I want to extend a sincere and enthusiastic thank you for your leadership in considering and moving forward with the rescheduling of marijuana from a Schedule I to a Schedule III controlled substance — a step that has already begun to reshape the national conversation around cannabis, research, and medical science. Your public remarks acknowledging that many people want this reclassification because it “leads to tremendous amounts of research that can’t be done unless you reclassify” reflect a willingness to look beyond old stigmas and recognize the potential for science and medicine to understand cannabis more fully. This shift — which would acknowledge cannabis as a substance with accepted medical use and a lower potential for abuse relative to Schedule I drugs — marks one of the most significant federal policy considerations in decades. By opening the door to research, innovation, an...
Post a Comment
Read more

Key differences Between Schedule I and Schedule III — What Rescheduling Marijuana Could Mean

  Key differences Between Schedule I and Schedule III — What Rescheduling Marijuana Could Mean Schedule I vs Schedule III Under the U.S. Controlled Substances Act (CSA), drugs are classified into schedules based on their accepted medical use, potential for abuse, and risk of dependence. Two key schedules in this context are Schedule I and Schedule III: Schedule I : Drugs with no currently accepted medical use in the U.S., a high potential for abuse , and potentially severe psychological or physical dependence. Examples include heroin, LSD, and currently, marijuana (cannabis). Schedule III : Drugs with accepted medical use , moderate to low potential for physical and psychological dependence, and a lower abuse risk compared to Schedules I or II. Examples include ketamine, anabolic steroids, testosterone, and certain codeine combinations (like Tylenol with codeine). Rescheduling marijuana from Schedule I to Schedule III would formally recognize its medical benefits...
Post a Comment
Read more

Free the Green: A Letter to President Donald J. Trump

  🇺🇸 Free the Green: A Letter to President Donald J. Trump An Open Plea from the American People & the Cannabis Family Legalize It President Trump, It’s time to Free the Green — to remove marijuana from the federal Schedule I classification, where it has been trapped since the Nixon era. A Law Without a Vote Few Americans realize that marijuana’s placement as a Schedule I drug — supposedly with “no medical value and a high potential for abuse” — was never voted on by Congress . It was assigned there in 1970 under the Controlled Substances Act by executive direction, intended as a temporary classification until a scientific commission could study the plant and make recommendations. That commission, known as the Shafer Commission , did complete its work — and in 1972, it recommended that marijuana should not be criminalized and should be removed from Schedule I entirely. The findings were ignored. Politics won. Science lost. And for over fifty years, that mi...
Post a Comment
Read more

What Is Nerolidol?

  Because of its sedative qualities, nerolidol-rich strains are often favored for evening use or for relaxation. What Is Nerolidol? Nerolidol is a naturally occurring sesquiterpene found in many plants. It has a distinctive aroma described as woody, floral, and slightly citrusy, often reminiscent of fresh ginger, jasmine, or bark. This terpene is known for its calming, sedative qualities and is commonly used in perfumes, cosmetics, and traditional herbal medicines. Nerolidol in Cannabis In cannabis, nerolidol contributes a subtle, complex aroma that blends woodsy and floral notes. It’s less common than some other terpenes but plays an important role in the overall scent and effect profile of certain strains. Strains high in nerolidol tend to be: Woody and floral Earthy with a touch of citrus Smooth and mellow Nerolidol itself does not produce intoxication but interacts with cannabinoids like THC and CBD to shape the overall experience. Effects Commo...
Post a Comment
Read more

What Is α-Bisabolol?

  α-Bisabolol-rich cannabis products are often preferred by those seeking gentle relaxation or relief from irritation and inflammation. What Is α-Bisabolol? α-Bisabolol is a naturally occurring terpene alcohol — one of the aromatic compounds found in many plants. It is best known for its soft, floral aroma and its calming, soothing properties, often associated with chamomile . Outside of cannabis, α-Bisabolol is widely found in: German chamomile Candeia tree Various medicinal herbs Skincare and cosmetic formulations Its gentle, slightly sweet scent has long been associated with calming effects and skin-soothing benefits. α-Bisabolol in Cannabis In cannabis, α-Bisabolol is a less common but highly valued terpene. When present in noticeable amounts, it contributes a smooth, floral aroma that can soften harsher terpene profiles. Cannabis strains containing α-Bisabolol often have aromas described as: Floral and chamomile-like Lightly sweet ...
Post a Comment
Read more